4%白蛋白溶液与醋酸林格液对体外循环心脏手术患者主要不良事件的影响:一项随机临床试验
该随机双盲单中心试验在2017—2020年纳入1407例体外循环心脏手术患者,1:1接受4%白蛋白(n=693)或醋酸林格液(n=693)作为体外循环预充及术中至术后24小时静脉容量替代,随访90天。主要终点为至少1项主要不良事件(死亡、心肌损伤、急性心衰、再次开胸、卒中、心律失常、出血、感染或急性肾损伤)。白蛋白组257/693例(37.1%)发生主要不良事件,林格液组234/693例(33.8%),相对风险1.10(95%CI 0.95-1.27;P=0.20),绝对差3.3个百分点(95%CI -1.7至8.4)。结论认为4%白蛋白未显著降低主要不良事件风险,不支持该场景使用4%白蛋白。
要点
- 体外循环心脏手术以4%白蛋白作预充和围术期容量替代,90天内主要不良事件37.1%(257/693)vs 醋酸林格液33.8%(234/693),相对风险1.10(95%CI 0.95-1.27;P=0.20),未达统计学显著。
- 绝对差3.3个百分点(95%CI -1.7至8.4),置信区间跨0。
- 研究液体中位用量:白蛋白组2150 mL(IQR 1598-2700 mL),林格液组3298 mL(IQR 2669-3500 mL)。
- 最常见严重不良事件:肺栓塞白蛋白组11例(1.6%)vs 林格液组8例(1.2%);心包切开后综合征两组各9例(1.3%);需ICU或住院再入院的胸腔积液中白蛋白组7例(1.0%)vs 林格液组9例(1.3%)。
- 作者结论:4%白蛋白未显著减少主要不良事件,这些发现不支持在该场景使用4%白蛋白。
适用人群与场景
- 接受体外循环下冠状动脉旁路移植术;主动脉瓣、二尖瓣或三尖瓣手术;不伴低温循环停止的升主动脉手术;和/或迷宫手术的患者。
- 单中心三级大学医院,2017—2020年,术后随访90天(末次随访2020年4月13日)。
处置流程与药物剂量
- 4%白蛋白溶液或醋酸林格液按1:1随机分配,作为体外循环预充液及术中至术后24小时的静脉容量替代溶液。
- 白蛋白组研究液体中位用量2150 mL(IQR 1598-2700 mL),醋酸林格液组3298 mL(IQR 2669-3500 mL)。
研究设计与关键结果
- 随机双盲单中心临床试验,1407例随机,1386例(99%)完成试验;平均年龄65.4岁(SD 9.9),男1091例(79%),女295例(21%)。
- 主要终点(至少1项主要不良事件:死亡、心肌损伤、急性心衰、再次开胸、卒中、心律失常、出血、感染或急性肾损伤):白蛋白组257/693例(37.1%)vs 醋酸林格液组234/693例(33.8%),相对风险1.10(95%CI 0.95-1.27;P=0.20),绝对差3.3个百分点(95%CI -1.7至8.4)。
- 最常见严重不良事件:肺栓塞白蛋白组11例(1.6%)vs 林格液组8例(1.2%);心包切开后综合征两组各9例(1.3%);需ICU或住院再入院的胸腔积液中白蛋白组7例(1.0%)vs 林格液组9例(1.3%)。
证据类型、等级与局限
- 证据类型:随机双盲单中心临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在体外循环心脏手术患者中,与醋酸林格液相比,4%白蛋白用于预充和围术期静脉容量替代未显著降低90天内主要不良事件风险,这些发现不支持在该场景使用4%白蛋白。
指南或共识出处
- ClinicalTrials.gov注册号NCT02560519。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In cardiac surgery, albumin solution may maintain hemodynamics better than crystalloids and reduce the decrease in platelet count and excessive fluid balance, but randomized trials are needed to compare the effectiveness of these approaches in reducing surgical complications.
OBJECTIVE: To assess whether 4% albumin solution compared with Ringer acetate as cardiopulmonary bypass prime and perioperative intravenous volume replacement solution reduces the incidence of major perioperative and postoperative complications in patients undergoing cardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, single-center clinical trial in a tertiary university hospital during 2017-2020 with 90-day follow-up postoperatively involving patients undergoing on-pump coronary artery bypass grafting; aortic, mitral, or tricuspid valve surgery; ascending aorta surgery without hypothermic circulatory arrest; and/or the maze procedure were randomly assigned to 2 study groups (last follow-up was April 13, 2020).
INTERVENTIONS: The patients received in a 1:1 ratio either 4% albumin solution (n = 693) or Ringer acetate solution (n = 693) as cardiopulmonary bypass priming and intravenous volume replacement intraoperatively and up to 24 hours postoperatively.
MAIN OUTCOMES AND MEASURES: The primary outcome was the number of patients with at least 1 major adverse event: death, myocardial injury, acute heart failure, resternotomy, stroke, arrhythmia, bleeding, infection, or acute kidney injury.
RESULTS: Among 1407 patients randomized, 1386 (99%; mean age, 65.4 [SD, 9.9] years; 1091 men [79%]; 295 women [21%]) completed the trial. Patients received a median of 2150 mL (IQR, 1598-2700 mL) of study fluid in the albumin group and 3298 mL (IQR, 2669-3500 mL) in the Ringer group. The number of patients with at least 1 major adverse event was 257 of 693 patients (37.1%) in the albumin group and 234 of 693 patients (33.8%) in the Ringer group (relative risk albumin/Ringer, 1.10; 95% CI, 0.95-1.27; P = .20), an absolute difference of 3.3 percentage points (95% CI, -1.7 to 8.4). The most common serious adverse events were pulmonary embolus (11 [1.6%] in the albumin group vs 8 [1.2%] in the Ringer group), postpericardiotomy syndrome (9 [1.3%] in both groups), and pleural effusion with intensive care unit or hospital readmission (7 [1.0%] in the albumin group vs 9 [1.3%] in the Ringer group).
CONCLUSIONS AND RELEVANCE: Among patients undergoing cardiac surgery with cardiopulmonary bypass, treatment with 4% albumin solution for priming and perioperative intravenous volume replacement solution compared with Ringer acetate did not significantly reduce the risk of major adverse events over the following 90 days. These findings do not support the use of 4% albumin solution in this setting.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02560519.
参考来源
- Pesonen E, Vlasov H, Suojaranta R, et al. Effect of 4% Albumin Solution vs Ringer Acetate on Major Adverse Events in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Clinical Trial. JAMA. 2022. PMID: 35852528. doi:10.1001/jama.2022.10461
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。